100. Pilot Study Demonstrating the Lung Microbiome as a Potential Marker for Lung Cancer
Roswell Park Comprehensive Cancer Center
Amherst, NY
United States - Contact Me
Dr. Yendamuri serves as a Professor of Oncology and Chair of Thoracic Surgery at the Roswell Park Comprehensive Cancer Center. He has developed clinical programs in the United States as well as India with a focus on pulmonary oncology and minimally invasive surgery. Dr. Yendamuri also serves as the Director of the Thoracic Surgery Laboratory at RPCCC. The focus of his translational work is the investigation of the obesity paradox in lung cancer and the amplification of the immune response to cancer through photodynamic therapy. These investigations have formed the basis for several investigator-initiated clinical trails that he leads. Dr. Yendamuri has been continuously funded by the NIH for over 10 years and has received grant support from DoD and several foundations. He has published ~170 peer reviewed manuscripts and 7 book chapters, and serves on the editorial boards of several major journals in thoracic oncology and thoracic surgery.
University of Michigan Medical Center
Ann Arbor, MI
United States - Contact Me
Rishindra M. Reddy, M.D., M.B.A. earned his undergraduate and medical degrees at Northwestern University, and completed his general surgery residency at Washington University-Barnes Jewish Hospital in St. Louis, Missouri. His spent two years during his residency, as a Clinical Research Fellow at the National Cancer Institute. He completed his Thoracic Surgery residency at the University of Washington and was a visiting fellow at Memorial Sloan Kettering Cancer Center. He is the endowed Jose Jose Alvarez Professor of Thoracic Oncology Research and is the Chair of the University of Michigan Comprehensive Robotic Surgery Program. Dr. Reddy's clinical interests include all aspects of general thoracic surgery including thoracic oncology, minimally invasive techniques, and therapy for end-stage lung disease including transplantation and lung volume reduction surgery. His academic interests include improving outcomes for patients with thoracic cancers, molecular targeting for thoracic cancers, and resident/medical student education.
Abstract
Methods: We collected central lobar bronchoalveolar lavage fluid (BALF) and brushing samples from early-stage lung cancer patients between July 2018 and May 2019 at a single academic center. Samples were collected from the affected lobe, ipsilateral non-affected lobe, and contralateral lobe. We performed microbial sequencing, untargeted metabolomics and cytokine analysis. We compared clinical and pathologic findings to microbiome signatures.
Results: Samples were collected from 28 patients with resectable lung cancer. Affected lobes displayed a different microbiome signature than contra-lateral lobes. In patents with adenocarcinoma (A), Microbiome diversity trended towards being less in patients with poor differentiated tumors vs those with well differentiated (p=0.08). The microbiome diversity in patients with A was similar to those with squamous cell cancer (SCC) (p=0.27). There were no differences in diversity or composition in the non-affected lobes of patients with A vs SCC. In evaluating the contralateral lobes, COPD patients trended towards having less diversity than those without COPD (p=0.1312).
Conclusions: The lung microbiome can potentially be used to differentiate between affected and non-affected lobes in the same patient. Further work is needed to understand the specific differences seen in the specific flora.